PRO-AZITHROMYCINE TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
28-05-2019
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)
제공처:
PRO DOC LIMITEE
ATC 코드:
J01FA10
INN (국제 이름):
AZITHROMYCIN
복용량:
250MG
약제 형태:
TABLET
구성:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250MG
관리 경로:
ORAL
패키지 단위:
30/100
처방전 유형:
Prescription
치료 영역:
OTHER MACROLIDES
제품 요약:
Active ingredient group (AIG) number: 0126072001; AHFS:
승인 상태:
APPROVED
승인 날짜:
2008-09-25
제품 특성 요약
PRODUCT MONOGRAPH
PR
PRO-AZITHROMYCINE
Azithromycin Tablets
250 mg
USP
ANTIBACTERIAL AGENT
PRO DOC LTÉE
2925, boul. Industriel
Laval, Québec
H7L 3W9 DATE OF REVISION:
May 28, 2019
Control number: 227600
_PRO-AZITHROMYCINE Product Monograph _
_Page 2 of 71_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................3
INDICATIONS AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS
......................................................................................................6
WARNINGS AND PRECAUTIONS
....................................................................................6
ADVERSE REACTIONS
....................................................................................................11
DRUG INTERACTIONS
.....................................................................................................18
DOSAGE AND
ADMINISTRATION.................................................................................23
OVERDOSAGE
...................................................................................................................24
ACTION AND CLINICAL PHARMACOLOGY
...............................................................25
STORAGE AND STABILITY
............................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................29
PART II: SCIENTIFIC INFORMATION
................................................................................30
PHARMACEUTICAL INFORMATION
............................................................................30
CLINICAL TRIALS
............................................................................................................31
DETAILED
PHARMACOLOGY.................................................................
전체 문서 읽기
